IZOTROPIC CORP. (1R3) - Total Liabilities
Based on the latest financial reports, IZOTROPIC CORP. (1R3) has total liabilities worth €6.03 Million EUR (≈ $7.05 Million USD) as of January 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 1R3 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
IZOTROPIC CORP. - Total Liabilities Trend (2022–2025)
This chart illustrates how IZOTROPIC CORP.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of IZOTROPIC CORP..
IZOTROPIC CORP. Competitors by Total Liabilities
The table below lists competitors of IZOTROPIC CORP. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
OPTHEA LTD
F:UKJ
|
Germany | €314.48 Million |
|
Hampton Financial Corp
V:HFC
|
Canada | CA$26.32 Million |
|
Myseum, Inc.
NASDAQ:MYSE
|
USA | $1.07 Million |
|
Landmark Property Development Company Limited
NSE:LPDC
|
India | Rs16.77 Million |
|
Amalgamated Industrial Steel Berhad
KLSE:2682
|
Malaysia | RM90.89 Million |
|
American Shared Hospital Service
NYSE MKT:AMS
|
USA | $31.03 Million |
|
Sarthak Metals Limited
NSE:SMLT
|
India | Rs127.36 Million |
|
Manho Rope&Wir
KO:001080
|
Korea | ₩22.54 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down IZOTROPIC CORP.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of IZOTROPIC CORP. to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 8.80 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IZOTROPIC CORP.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IZOTROPIC CORP. (2022–2025)
The table below shows the annual total liabilities of IZOTROPIC CORP. from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-04-30 | €5.27 Million ≈ $6.17 Million |
+29.30% |
| 2024-04-30 | €4.08 Million ≈ $4.77 Million |
+16.01% |
| 2023-04-30 | €3.52 Million ≈ $4.11 Million |
+32.99% |
| 2022-04-30 | €2.64 Million ≈ $3.09 Million |
-- |
About IZOTROPIC CORP.
Izotropic Corporation, a research and development company, develops diagnostic products for detecting breast cancers. The company develops and commercializes IzoView, a CT diagnostic imaging device with a platform of targeted uses offering high resolution, true 3D dedicated breast imaging with 360-degree image acquisition and can be used with or without injectable contrast. Izotropic Corporation … Read more